Back to today’s briefing

Story perspectives

FDA's Crackdown Drives Consumers to Risky Weight Loss Supplements

4/23/2025

26 4

Summary

Story summary

The FDA's recent action against compounded weight loss drugs Wegovy and Zepbound has pushed consumers towards unregulated GLP-1 dietary supplements. Experts caution that these products, often falsely advertised, lack scientific support and may not deliver results. They stress the importance of consulting healthcare providers, as no supplement can match the efficacy of GLP-1 medications.

1 of 1

Story summary

The FDA's recent action against compounded weight loss drugs Wegovy and Zepbound has pushed consumers towards unregulated GLP-1 dietary supplements. Experts caution that these products, often falsely advertised, lack scientific support and may not deliver results. They stress the importance of consulting healthcare providers, as no supplement can match the efficacy of GLP-1 medications.